

1 **SwissGenVar: A platform for clinical grade interpretation of genetic variants to**
2 **foster personalized health care in Switzerland**

3 Dennis Kraemer¹, Dillenn Terumalai², Maria Livia Famiglietti³, Isabel Filges⁴, Pascal Joset⁴,
4 Samuel Koller⁵, Fabienne Maurer⁶, Stéphanie Meier⁴, Thierry Nospikel⁷, Javier Sanz⁸,
5 Christiane Zweier⁸, Marc Abramowicz⁷, Wolfgang Berger^{5,9,10}, Sven Cichon⁴, André Schaller⁸,
6 Andrea Superti-Furga⁶, Valérie Barbié², Anita Rauch^{1*}

7
8 1. Institute of Medical Genetics (IMG), University of Zurich (UZH), CH-8952 Schlieren/Zurich,
9 Switzerland.

10 2. Swiss Institute of Bioinformatics (SIB), Clinical Bioinformatics, Campus Biotech, CH-1202
11 Geneva, Switzerland.

12 3. Swiss Institute of Bioinformatics (SIB), Swiss-Prot group, Centre Medicale Universitaire
13 (CMU), CH-1211 Geneva, Switzerland.

14 4. Medical Genetics, Institute of Medical Genetics and Pathology, University Hospital Basel
15 and University of Basel, CH-4031 Basel, Switzerland.

16 5. Institute of Medical Molecular Genetics (IMMG), University of Zurich (UZH), CH-8952
17 Schlieren/Zurich, Switzerland.

18 6. Division of Genetic Medicine, Lausanne University Hospital (CHUV), CH-1011 Lausanne,
19 Switzerland.

20 7. Genetic Medicine Division, Diagnostics Dept./Center for Genomic Medicine, Geneva
21 University Hospitals (HUG), Geneva, Switzerland.

22 8. Department of Human Genetics, Inselspital, Bern University Hospital, CH-3010 Bern,
23 Switzerland.

24 9. Neuroscience Center Zurich (ZNZ), University and ETH Zurich, Zurich, Switzerland.

25 10. Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich,
26 Switzerland.

27 ***Corresponding author:** Prof. Dr. med. Anita Rauch, Institute for Medical Genetics,
28 University of Zurich, Winterthurerstrasse 12, CH-8952 Schlieren/Zurich/Switzerland, email: anita.rauch@medgen.uzh.ch
29

30 **Keywords:** *SwissGenVar*, Switzerland; NGS; expert-curated variant interpretation; national
31 mutation database, genotype-phenotype database; personalized medicine
32

33 **Abstract**

34 Large-scale next-generation sequencing (NGS) germline testing is technically feasible today,
35 but variant interpretation represents a major bottleneck in analysis workflows including the
36 extensive variant prioritization, annotation, and time-consuming evidence curation. The scale
37 of the interpretation problem is massive, and variants of uncertain significance (VUS) are a
38 challenge to personalized medicine. This challenge is further compounded by the complexity
39 and heterogeneity of standards used to describe genetic variants and associated phenotypes
40 when searching for relevant information to inform clinical decision-making.

41 For this purpose, all five Swiss academic Medical Genetics Institutions joined forces with the
42 Swiss Institute of Bioinformatics (SIB) to create *SwissGenVar* as a user-friendly nationwide
43 repository and sharing platform for genetic variant data generated during routine diagnostic
44 procedures and research sequencing projects. Its objective is to provide a protected
45 environment for expert evidence sharing about individual variants to harmonize and up-scale
46 their significance interpretation at clinical grade following international standards. To
47 corroborate the clinical assessment, the variant-related data are combined with consented
48 high-quality clinical information. Broader visibility will be gained by interfacing with international
49 databases, thus supporting global initiatives in personalized health care.

50

51 **1. Introduction**

52 Assessment of individual genetic risk factors and classification of molecular disease
53 based on genetic contributions are hallmarks of personalized medicine [1-5]. Next to common
54 genetic variants predisposing to, or modulating common diseases, newer evidence also
55 indicates a significant role of individually rare variants in frequently mutated genes with strong
56 functional consequences [6, 7]. Large-scale germline genetic testing is technically feasible
57 today but is hampered by the difficulties in interpreting the clinical significance of variants, lack
58 of knowledge about genotype-phenotype correlation, and long-term clinical history [8, 9].

59 Accurate pathogenicity interpretation of genetic variants is not only crucial for appropriate
60 medical decision-making based on genetic evidence [10] but also for the correct stratification
61 of research findings by genetic results [11]. A variety of international database initiatives aim
62 to facilitate genetic variant assessment; however, these often are restricted to specific genes
63 and/or (types of) genetic diseases/alterations and contain insufficient or contradictory,
64 sometimes even incorrect public entries [12, 13], which mostly fail to provide accompanying
65 valid clinical data for variant interpretation in their respective phenotypic contexts [14, 15].
66 Moreover, since genetic variation commonly differs among ethnicities, international data
67 collection may not be representative and comprehensive for specific populations. The
68 importance of local and national genetics has been exemplified by the Genome of the
69 Netherlands initiative [16]. Therefore, the next big challenge in personalized medicine will be
70 the expansion of high-quality genotype-phenotype databases providing "knowledge" over
71 "data" to enable, without dictating, accurate clinical care due to rigid quality management and
72 a sustainable expert variant curation and classification process [17, 18].

73 In Switzerland, research including human genetic data, as well as diagnostic germline
74 genetic testing is strictly regulated and subject to regular quality control and accreditation
75 procedures. Accordingly, research involving germline genetic data and diagnostic genetic
76 testing is mainly pursued by highly specialized centers including the university and cooperating
77 clinical centers for Medical/Human Genetics. The use of next-generation sequencing (NGS)
78 technologies as the standard of care creates a rich source of genetic data with an in-depth
79 clinical variant assessment that currently is not collected systematically. In Switzerland so far,
80 there exists no nationwide academic/public database for genetic variants obtained from
81 diagnostic procedures or sequencing research projects. Therefore, the considerable potential
82 to promote sharing diagnostic-grade genomic data with patient-related consented high-quality
83 clinical information remains largely untapped. Besides data protection issues, this may be
84 explained, particularly for Swiss institutions, by the previous lack of agreed harmonized
85 standards and concepts for genetic data collection and exchange as well as the absence of a
86 suitable and secure repository infrastructure for genomic and related patient data.

87 To address these difficulties and leverage the high-quality genetic and accompanying
88 clinical data generated in Swiss academic institutions, all five Swiss university centers for
89 Medical/Human Genetics joined forces with the Swiss Institute of Bioinformatics (SIB, Clinical
90 Bioinformatics) in a nationwide effort to create the *SwissGenVar* platform within the framework
91 of a Swiss Personalized Health Network (SPHN) [19] infrastructure development project
92 (project page available at [20]). *SwissGenVar* aims at providing a protected nationwide
93 repository for germline variants identified in patients by Swiss clinical genetic laboratories with
94 accompanying high-quality clinical data and an efficient joint platform for harmonization and
95 up-scaling of expert-curated variant interpretation. However, *SwissGenVar* not only fosters
96 harmonization and inclusion of diagnostic data, but also of data generated within research
97 projects using genomic sequencing approaches. To this end, *SwissGenVar* ensures
98 interoperability with international databases and the methodological and technical
99 prerequisites for national and international sharing/storage of genomic data and evidence for
100 standardized variant pathogenicity assessment, to facilitate consensus variant classification
101 by clinical genetic experts. Furthermore, *SwissGenVar* allows the harvesting of patient-
102 consented clinical data generated during routine health care to assess the clinical significance
103 of a variant for a specific disease in synopsis with associated phenotypic features.

104 Within this project, we, therefore, defined an interoperable set of genetic and non-
105 identifying clinical data for variant data sharing/storage and clinical interpretation, a consistent
106 genetic variant file upload and annotation process as well as a data ontology appropriate for
107 the creation of a protected nationwide germline variant database with accompanying high-
108 quality clinical data and significance interpretation. The accessibility for clinicians and
109 researchers has been realized through an efficient, scalable, and user-friendly IT
110 infrastructure, integrated within the secure BioMedIT [21] landscape of SPHN. Currently,
111 *SwissGenVar* is accessible to the project partners only, but with a scope for expansion to
112 further academic and non-academic institutions to establish itself as the Swiss one-stop
113 platform for the interpretation/understanding of genetic germline variants. Thus, *SwissGenVar*

114 may substantially foster personalized health care, and, on the other hand, be a necessary first
115 step to scale-up clinical-grade genetic testing and data sharing in Switzerland.

116

117 **2. Materials and Methods**

118 **2.1 Sensitive data hosting and transfers**

119 The *SwissGenVar* infrastructure development project has been initially funded by the
120 Swiss Personalized Health Network (SPHN) [19] initiative which builds on the Swiss national
121 BioMedIT infrastructure, specifically implemented for hosting sensitive data. It, therefore, uses
122 all tools provided by those initiatives and follows their requirements.

123 The *SwissGenVar* application and data are hosted on the secure SENSE (Secure
124 Sensitive Data Processing Platform) BioMedIT [21] node in Lausanne and comply with the
125 SPHN and BioMedIT tools and the related Information Security Policy [22]. Data transfers are
126 ensured by the SPHN SETT (Secure Encryption and Transfer Tool) data transfer tool [23],
127 which encrypts, securely transfers, and decrypts data.

128 Users' identity and access are managed using the BioMedIT central Keycloak [24]
129 instance, which requires SWITCH eduID [25] two-factor authentication to log in. Keycloak is
130 an open-access IAM platform that secures web applications and RESTful web services using
131 standard protocols such as OAuth2, OpenID Link, and SAML 2.0. In addition, access to the
132 system is restricted to the whitelisted IP (Internet Protocol) address ranges of each
133 participating institution.

134 All data used for the development of the platform and depicted in the figures are for
135 fictitious individuals, not real patients.

136

137 **2.2 Software development**

138 *SwissGenVar* is a web-based application, which backend is written in PHP (using the
139 Laravel framework) and relies on a PostgreSQL database. The frontend is based on Vue.js
140 (using the Nuxt framework). The bioinformatics pipeline is running on a SLURM cluster.

141

142 **2.3 Public data sources**

143 For all variants in the VCF (Variant Call Format) files, some public information is
144 automatically gathered by the *SwissGenVar* platform using a local instance of the Ensembl
145 Variant Effect Predictor (VEP) [26] deployed on the SENSE BioMedIT node. This information
146 currently includes the variant type and effect, the genomic position of the variant, and the
147 HGVS (Human Genome Variation Society) variant nomenclature [27].

148

149 **3. Results**

150 **3.1 *SwissGenVar* governance and layers of access**

151 For implementation and administration of *SwissGenVar*, a multicenter consortium
152 among all five academic centers for Medical Genetics in Switzerland and the Swiss Institute of
153 Bioinformatics (SIB) (Figure 1) has been formed, which is governed by the Steering Board, as
154 defined in the *SwissGenVar* Consortium Agreement. To combine the use for research and the
155 highest level of data protection, the platform is composed of two different modules with different
156 potential layers of access, which are specified by the Data Transfer and Use Agreement
157 (DTUA). The access-controlled instance is intended to share genetic data and non-identifying
158 associated clinical/demographic metadata in view-only mode, including data submitted by any
159 other registered group. Registered users belonging to a registered group may in addition
160 modify their own data or metadata. The access to the data stored in the access-controlled
161 instance is restricted to registered users of the consortium (full access layer). However, upon
162 approval by the Steering Board, data from the access-controlled instance (including personal
163 data) may be made accessible to users belonging to a third-party group if required for a specific
164 research study and if authorized by the competent ethics committee (restricted access layer).
165 By contrast, the public instance aims to make stand-alone variants and aggregated
166 patient/proband data (without any information related to the specific patient/proband or
167 sample) publicly available and will be freely accessible by all interested parties without
168 registration (public access layer).

169 **3.2 Standardized *SwissGenVar* dataset specifications**

170 One of the key concepts of *SwissGenVar* is the combination of diagnostic-grade
171 genetic variant-related data and accompanying consented high-quality basic clinical
172 information to corroborate their diagnostic utility. To harmonize the variant-related and
173 phenotypic ontologies, a cross-expert working group defined a minimal and an extended
174 genetic and clinical data set pertinent for data sharing/storage and the standardized
175 interpretation of the clinical significance of genetic variants, which have been approved by the
176 *SwissGenVar* board. After several rounds of thorough discussions and board meetings,
177 dedicated clinical and laboratory working groups, which were managed by clinical experts for
178 the addressed issue, elaborated a comprehensive and granular portfolio of parameters and
179 functionalities needed for the objectives of *SwissGenVar*.

180 To ensure interoperability with international databases and other SPHN projects,
181 *SwissGenVar* follows established international standards and the SPHN guidelines for
182 Interoperability Data Standard and Tool Collection [22], whenever applicable. For most items,
183 well-defined existing ontologies are used (Tab. 1). However, for the data fields relevant to the
184 *SwissGenVar* project where no appropriate data standard was available, the consortium had
185 to define and adapt an internal data catalogue reflecting the consensus between the practices
186 at the different partner institutions.

187 Furthermore, *SwissGenVar* enables automated variant annotation from a variety of
188 sources and implements direct links to the well-established NCBI ClinVar [28] and Single
189 Nucleotide Polymorphism Database (dbSNP) [29] as well as to Human Gene Mutation
190 Database (HGMD) [30], DECIPHER [31], LOVD (Leiden Open Variation Database) [32] and
191 SVIP-O [33], the latter being a Swiss SPHN platform for the clinical interpretation of genetic
192 variants in oncology (Swiss Variant Interpretation Platform for Oncology). Additionally, the
193 widely-used predictive algorithms SIFT (Sorting Intolerant From Tolerant) [34] and PolyPhen-
194 2 [35] for *in silico* assessment of amino acid substitutions are implemented using VEP.

195

196 **3.3 Data management and application workflow**

197 The project partners provide high-quality genetic data mostly from NGS procedures
198 (exome and genome sequencing or other methods in the form of VCF files [Variant Call
199 Format]) either derived from research studies or diagnostic testing with general or dedicated
200 *SwissGenVar* consent, which are complemented by a minimal set of basic clinical information
201 from the relevant medical history of the patient (Figure 2). These genetic and clinical data are
202 generated either directly by the involved laboratories or by the hospital Clinical Data
203 Warehouses (CDW), depending on each partner institution's setup. In both cases, genetic
204 data are encrypted and securely transferred using the SPHN BioMedIT transfer tool [23] and
205 are stored and accessed according to BioMedIT access and security standards [24, 25].
206 Subsequently, after decryption and parsing of the transferred files, patient entries are created
207 and variant calls from the VCF files are loaded into the platform. Before being loaded, the
208 genetic data are going through a technical basic check-up to ensure compliance with the
209 requested VCF file format. The user can then select individual variants as "of interest" so that
210 they are displayed in priority on the interface.

211 Additionally, using a local instance of the Ensembl Variant Effect Predictor (VEP),
212 *SwissGenVar* automatically retrieves publicly available annotations for each variant like
213 gnomAD (Genome Aggregation Database) population frequency, variant effect, and the
214 presence of the variant in public databases such as NCBI ClinVar. The implementation of
215 additional public annotations by the integration of APIs from further data sources is being
216 investigated. For the patients' phenotypic features, *SwissGenVar* allows clinical experts to
217 manually enter clinical information and specific findings relevant to the variant assessment on
218 their patients *via* its web interface using standardized vocabularies agreed upon during the
219 project. Only the data providers are allowed to modify their own data in case corrections or
220 clinical data are added.

221

222 **3.4 *SwissGenVar* database structure, data query, and data display**

223 We developed a graphical user interface to visualize and query the data, enabling the
224 users to explore genetic variants in a gene and/or patient of interest or to retrieve patients with

225 specific phenotypic features. Queries can be issued either from a variant or a patient query
226 page (Figure 3). This interface allows the creation of a custom query based on the user's
227 interest, with one or multiple criteria filters to search the database and display all the variants
228 or patients matching the selected filtering criteria. The query result is displayed in a variant or
229 patient results table, respectively, that show only selected comparable/searchable information
230 items. However, once a specific variant or patient is selected by clicking on the corresponding
231 row of a results table, the user can access the individual detailed page providing more granular
232 information about the variant or the patient of interest. Thus, the detailed variant page
233 comprises a table of all the patients harboring this specific variant along with selected related
234 information as well as shows automatically retrieved variant annotations as detailed in Tab. 1.
235 The detailed patient page contains a table of variants detected in the patient of interest
236 (obtained from the VCF files) and provides diverse phenotypic features. When no filter is used,
237 the variant and patient tables list all the variants of interest by default and patients present in
238 the database. The pages "Uploaded patients" and "Transferred VCF files", which are
239 accessible *via* the "My Data" selection panel or menu at the top of the interface, support the
240 users in the management of their own data and provide an overview of their submitted patients
241 and transferred VCF files including their (validation) status. Under the detailed page of the
242 individual patients, the clinical partner of the submitting institution can complement the patient
243 entry with a standardized data set of non-identifying clinical and demographical information
244 and add the granular history of medical contacts with the clinical/phenotypic findings obtained
245 and potential genetic diagnoses. Additionally, the data provider can prioritize clinically
246 (potentially) significant variants by flagging them as of interest (by clicking on the star symbol
247 on the left in the variant table), which is likewise possible directly on the detailed page of the
248 respective transferred VCF file. Finally, the application provides the option of adding variants
249 and patients to a user's favorite list under the individual detailed page. A notification system
250 will be established to inform the users about any changes or updates concerning their variants
251 or patients of interest.

252

253 4. Discussion

254 *SwissGenVar* aims to use datasets with general consent or with dedicated
255 *SwissGenVar* consent to evaluate the landscape of (clinically relevant) genetic variants in
256 Switzerland to improve variant interpretation and risk assessment by studying genotype-
257 phenotype relation and the natural history of genetic predispositions and disorders. This shall
258 increase our knowledge and result in respective standard operating procedures and structures
259 for improved patient care. Therefore, *SwissGenVar* intends to be a nationwide repository for
260 genetic findings in available and consented genetic data sets across all five academic Medical
261 Genetic institutions in Switzerland and to jointly assess their clinical significance to implement
262 standard operating procedures and improved genetic diagnostics and patient care. As main
263 achievement, *SwissGenVar* allows for the collection and sharing of genetic and associated
264 clinical data *via* a secure data transfer and access/query by the project partners. At the same
265 time, it provides a platform for knowledge sharing about variant-related evidence to harmonize
266 and upscale their significance interpretation at clinical grade with interoperability with
267 international efforts.

268 For this purpose, *SwissGenVar* supports granular multifactorial filtering for variants and
269 patients in separate query interfaces and details "in-house" variant-related and clinical
270 evidence such as data from local mutation and clinical databases, and segregation as well as
271 experimental analyses. Additionally, *SwissGenVar* enables its users to submit published
272 information like published literature reports and functional studies as well as includes publicly
273 retrievable variant annotations and links to well-established variant databases following
274 international standards. Compared to existing genotype-phenotype/variant databases, the
275 integration of the complete set of variant calls from the transferred VCF files and of the granular
276 history of medical contacts and portfolio of phenotypic findings can be regarded as a big
277 advantage in addition to the collection of genetic variants found in Swiss subpopulations [45,
278 46]. This allows for the comprehensive clinical assessment of variants in the synopsis of co-
279 occurring candidate variants and the respective clinical features of the variant-carrying
280 individual, which is supported by the option to flag several variants as of interest in the

281 corresponding VCF files. To prompt expert discussions about significance interpretation, a
282 notification system will inform users about any changes or updates concerning the
283 classification of individual variants or patients of interest. Finally, the *SwissGenVar* project has
284 strongly contributed to harmonizing diagnostic practices among the participating institutions by
285 defining and standardizing ontologies for variant and related clinical data. The ontology
286 catalogue was provided to the SPHN Data Coordination Center (DCC) [47] to serve as a basis
287 for other (and follow-up) projects in medical genetics.

288 Individual findings may be followed up and, depending on the consent provided, clearly
289 pathogenic findings with high predictive value may be fed back to the referring medical
290 geneticist for genetic counseling of the patient. The knowledge gained for individual variants
291 shall be annotated in the *SwissGenVar* database and may become publicly accessible in a
292 public outlet of the platform integrating interfaces with international database efforts. So far,
293 the platform is available to partner groups only, but with a scope for expansion to further
294 academic and non-academic institutions.

295

296 **5. Conclusions**

297 In conclusion, *SwissGenVar* provides a protected platform for the nationwide collection
298 of genetic germline variants and the sharing of related evidence and curated variant
299 significance interpretations by clinical genetic experts, integrating a consistent genetic variant
300 file upload and semi-automated annotation/curation pipeline. Thus, *SwissGenVar* may be
301 regarded as a necessary first step to harmonize and scale-up clinical-grade genetic testing in
302 Switzerland, thereby fostering personalized health research involving genetic risk stratification
303 and disease classifications.

304

305 **Author Contributions:** Conceptualization: M.A., W.B., S.C., A.S., A.S.F., V.B. and A.R.;
306 Methodology: D.K., D.T., L.F., I.F., P.J., S.K., F.M., S.M., T.N., J.S., C.Z., M.A., W.B., S.C.,
307 A.S., A.S.F., V.B. and A.R.; Software: D.T. and V.B.; Data Curation: D.K., D.T., L.F., I.F., P.J.,

308 S.K., F.M., S.M., T.N., J.S., C.Z., M.A., W.B., S.C., A.S., A.S.F., V.B., A.R.; Writing – Original
309 Draft Preparation, D.K., D.T., V.B. and A.R.; Writing – Review & Editing: D.K., D.T., L.F., I.F.,
310 P.J., S.K., F.M., S.M., T.N., J.S., C.Z., M.A., W.B., S.C., A.S., A.S.F., V.B., A.R.; Visualization:
311 D.K., D.T., V.B. and A.R.; Project Administration: A.R.; Funding Acquisition: A.R.

312 **Funding:** This platform development was funded as infrastructure development project
313 (2018DEV13) by the Swiss Personalized Health Network (SPHN).

314 **Institutional Review Board Statement:** Not applicable.

315 **Informed Consent Statement:** Not applicable. All presented data are for fictitious individuals,
316 not real patients.

317 **Data Availability Statement:** The *SwissGenVar* documentation and public website are
318 available at <https://pages.sib.swiss/project/swissgenvar-doc/> and <https://pages.sib.swiss/project/swissgenvar/>, respectively. The project GitLab site is available at URL
319 <https://gitlab.sib.swiss/clinbio/swissgenvar/sgv-knowledge/-/tree/master>.
320

321 **Conflicts of Interest:** The authors declare no conflict of interest.

322 **Figure legends**

323 **Figure 1.** Involved institutions of the *SwissGenVar* consortium: University Hospital Basel,
324 Medical Genetics; Department of Human Genetics, Inselspital, Bern University Hospital;
325 Medical Genetics Service/Center for Genetic Medicine, Geneva University Hospital (HUG);
326 Medical Genetics Service/Division of Genetic Medicine, Lausanne University Hospital (CHUV);
327 Institute of Medical Genetics (IMG), University of Zurich (UZH); Institute of Medical Molecular
328 Genetics (IMMG), University of Zurich (UZH); Swiss Institute of Bioinformatics (SIB); Swiss
329 Personalized Health Network (SPHN).

330 **Figure 2:** Synopsis of the clinical (*orange*) and laboratory (*grey*) working groups. These
331 elaborated minimal and extended data sets of genetic and clinical data as well as functionalities
332 pertinent to the collection, sharing, and interpretation of genetic variants. At the operational
333 level, a regularly meeting cross-expert team was installed for content implementation.

334 **Figure 3.** *SwissGenVar* application workflow. The *SwissGenVar* partners provide the genetic
335 variant data to the *SwissGenVar* database in VCF format. The data are encrypted and securely
336 transferred (*step 1*) using the SPHN Secure Encryption and Transfer Tool (SETT). Upon
337 transfer to the *SwissGenVar* private/main application server, the files are decrypted and parsed
338 to create patient entries and load the genetic variants into the platform. The variant entries are
339 automatically enriched with selected external public annotations (*step 2*). At this stage, the
340 partners can connect to their protected account using two-factor authentication to check the
341 transfer of their data files and start adding clinical information on their patients directly on the
342 *SwissGenVar* interface (*step 3*). They can also query the full database to go to specific patient
343 pages and select variants of interest using multiple pre-defined filters (*step 4*). In a future step,
344 *SwissGenVar* will also integrate a publicly accessible platform of aggregated variant-related
345 and clinical information for personalized medicine research.

346 **Figure 4.** *SwissGenVar* variant (**A**) and patient (**B**) query pages. These pages consist of the
347 filters bar (1); table of all/matching variants/patients with selected annotations (2); search panel
348 to switch between variant and patient query page (3); selection panel "My data" (4) to view and

349 edit the patients submitted by the user (under "Uploaded patients" overview and the detailed
350 page (**C**)), respectively) to view the personal lists of the variants/patients of interest, or to view
351 and edit the VCF files transferred by the user (under "Transferred VCF files" overview and the
352 detailed page (**D**), respectively); menu bar (5) with a personal account and link to VCF upload
353 service. By clicking on a row of the respective table, the users will be redirected to the individual
354 detailed page providing further information, and in the case of the "My patients" and
355 "Transferred VCF files" pages, to edit their own patients and VCF files. Of note, all presented
356 data are for fictitious individuals, not real patients.

Figure 1




Figure 2




Figure 3




Figure 4 (A)

VARIANTS | PATIENTS SwissGenVar

Variants

[My account](#) | [My transferred VCF files](#) | [My patients](#) | [My lists of interest](#) | [Documentation](#)

Search

- Variants
- Patients
- My Data
- My patients
- My favorite variants
- My favorite patients
- My transferred VCF files

Our database contains more than 797 variant(s)

GENE HUGO SYMBOL ^ | CLINICAL SIGNIFICANCE ^ | VARIANT EFFECT ^ | VARIANT TYPE ^ | LOCATION v | RESET FILTERS

24 variant(s)

Clinical significance	ClinVar annotation	Variant type	Genomic position	Gene name	Cytogenetic location	ISCN name	HGVS	Variant effect
-	B	SNV	chr1:949608-949608	ISG15			1:g.949608G>A NM_005101.4:c.248G>A NP_005092.1:p.Ser83Asn	Missense Variant
-	B	SNV	chr1:955597-955597	AGRN			1:g.955597G>T NM_001305275.2:c.45G>T NP_001292204.1:p.Pro1...	Synonymous Variant
-	B	SNV	chr1:26786627-26786627	DHDDS LOC101928324			1:g.26786627G>A NM_024887.3:c.757G>A NP_079163.2:p.Val253M...	Missense Variant

Inheritance Zygosity Co-occurrences Subm. inst. Coll. method Det. method

Wilson disease 3

	Heterozygous	+	HUG		Southern Blot
	Homozygous	-	CHUV		FISH (IFISH or MFISH)
	Heterozygous	+	IMGZ		NGS-based CNV detection (Panel/WES/WGS)

Single nucleotide variant -

chr1:949608-949608

Gene(s): **ISG15**

Locus Reference Genomic (LRG): Not available

Locus type: Not available

Locus subjected to imprinting: Not available

HGVS genomic: **1:g.949608G>A**

Minor Allele Frequency (gnomAD): **0.3389**

ADD THIS VARIANT TO MY FAVORITE LIST

TRANSCRIPT ALLELES	KNOWN VARIANTS	COMPUTATIONAL PREDICTIONS	STUDIES	EXTERNAL RESOURCES
Transcript alleles		Variant effect	Affected proteins	
NM_000053.4:c.1934T>G		missense_variant	NP_000044.2:p.Met645Arg	
NM_001330578.1:c.1934T>G		missense_variant	NP_001317507.1:p.Met645Arg	

Patients

Figure 4 (B)

Our database contains more than 10 patient(s)

ETHNICITY ^ | SUBMITTING INSTITUTION ^ | CLINICAL GENDER ^ | CHROMOSOMAL SEX ^ | CANTON OF ORIGIN ^ | RESET FILTERS

10 patient(s)

Patient ID	Submit. Inst.	Age	Clinical gender	Chrom. sex	Ethnicity	Diagnoses	Phenotypes
#HUG_PATIENT_1	SIB	16	Male	XY	Non-Finnish European	Intellectual developmental disorder 59 Wilson disease	Arachnodactyly Generalized hypotonia Joint hypermobility + 4 phenotypes

GENE HUGO SYMBOL ^ | CLINICAL SIGNIFICANCE ^ | VARIANT EFFECT ^ | VARIANT TYPE ^

LOCATION v | RESET FILTERS

3 variant(s)

Clinical significance	Variant type	Genomic position	Gene name	HGVS	Variant effect
-	SNV	chr1:752894-752894	FAM87B	1.g.752894T>C NR_103536.1.n.144T>C	Non Coding Transcript Exon Variant
-	SNV	chr1:762273-762273	LINC00115 LINC01128	1.g.762273G>A NR_024321.1.n.630C>T	Non Coding Transcript Exon Variant
-	SNV	chr1:762485-762485	LINC00115 LINC01128	1.g.762485C>A NR_024321.1.n.418G>T	Non Coding Transcript Exon Variant

Rows per page: 10 | 1-3 of 3

SIB

Patient#HUG_PATIENT_1

Diagnosis: Intellectual developmental disorder 59 | Wilson disease

Clinical indication: Osteoarthritis | Hepatic failure

Clinical symptoms and physical findings: Arachnodactyly | Generalized hypotonia | Joint hypermobility | Muscular hypotonia | Myoclonus | Tall stature | Tremor

Age: 16

Clinical gender: Male

Chromosomal sex: XY

Ethnicity: Non-Finnish European

Canton: Geneva

ADD THIS PATIENT TO MY FAVORITE LIST

DIAGNOSIS | CLINICAL SYMPTOMS AND PHYSICAL FINDINGS | CONTACT

Intellectual developmental disorder 59 | Clinical indication: Osteoarthritis | Index patient

Date	Event	Diagnosis	Age	Clinical status	Detection methods
October 26, 2021	Diagnosis	Intellectual developmental disorder 59	16	Affected	
October 12, 2021	Visit	Intellectual developmental disorder 59	16		sequencing

Wilson disease | Clinical indication: Hepatic failure | Index patient

Date	Event	Diagnosis	Age	Clinical status	Detection methods
June 20, 2022	Diagnosis	Wilson disease	16	Affected	sequencing

Figure 4 (C)

Uploaded patients



2 patient(s)

Patient ID	Submit. Inst.	Age	Clinical gender	Chrom. sex	Ethnicity	Diagnoses	Phenotypes
#IMGZ_PATIENT_1	IMGZ						
#IMGZ_PATIENT_2	IMGZ						



30 variant(s)

Variant of interest	Clinical significance	Variant type	Genomic position	Gene name	HGVS	Variant effect
☆	-	SNV	chr1:14653-14653	WASH7P DDX11L1 MIR6859-1	1:g.14653C>T	Non Coding Transcript Exon Variant
☆	-	SNV	chr1:14907-14907	WASH7P DDX11L1 MIR6859-1	1:g.14907A>G	Intron Variant
☆	-	SNV	chr1:14930-14930	WASH7P DDX11L1 MIR6859-1	1:g.14930A>G	Intron Variant
☆	-	SNV	chr1:15118-15118	WASH7P DDX11L1 MIR6859-1	1:g.15118A>G	Intron Variant
☆	-	SNV	chr1:15211-15211	WASH7P DDX11L1 MIR6859-1	1:g.15211T>G	Intron Variant
☆	-	SNV	chr1:15688-15688	WASH7P DDX11L1 MIR6859-1	1:g.15688C>T	Intron Variant

IMGZ

Patient#IMGZ_PATIENT_1

Birth year

Clinical gender

Chromosomal sex

Ethnicity

Canton

Is deceased?

CANCEL **SAVE**

Figure 4 (D)

Transferred VCF files



2 VCF file(s)

VCF ID	Original filename	Status	Validation status	Received on	Updated on
#5	Patient3852_IMGZ.vcf	✓	✓	October 12, 2021	October 12, 2021
#6	Patient98_IMGZ.vcf	✓	✓	October 12, 2021	October 12, 2021

GENE HUGO SYMBOL ^
CLINICAL SIGNIFICANCE ^
VARIANT EFFECT ^
VARIANT TYPE ^

LOCATION v
RESET FILTERS

30 variant(s)

Variant of interest	Clinical significance	Variant type	Genomic position	Gene name	HGVS	Variant effect
☆	-	SNV	chr1:14653-14653	<div style="background-color: black; color: white; padding: 2px; display: inline-block;">WASH7P</div> <div style="background-color: black; color: white; padding: 2px; display: inline-block;">DDX11L1</div> <div style="background-color: black; color: white; padding: 2px; display: inline-block;">MIR6859-1</div>	1:g.14653C>T	Non Coding Transcript Exon Variant
☆	-	SNV	chr1:14907-14907	<div style="background-color: black; color: white; padding: 2px; display: inline-block;">WASH7P</div> <div style="background-color: black; color: white; padding: 2px; display: inline-block;">DDX11L1</div> <div style="background-color: black; color: white; padding: 2px; display: inline-block;">MIR6859-1</div>	1:g.14907A>G	Intron Variant
☆	-	SNV	chr1:14930-14930	<div style="background-color: black; color: white; padding: 2px; display: inline-block;">WASH7P</div> <div style="background-color: black; color: white; padding: 2px; display: inline-block;">DDX11L1</div> <div style="background-color: black; color: white; padding: 2px; display: inline-block;">MIR6859-1</div>	1:g.14930A>G	Intron Variant
☆	-	SNV	chr1:15118-15118	<div style="background-color: black; color: white; padding: 2px; display: inline-block;">WASH7P</div> <div style="background-color: black; color: white; padding: 2px; display: inline-block;">DDX11L1</div> <div style="background-color: black; color: white; padding: 2px; display: inline-block;">MIR6859-1</div>	1:g.15118A>G	Intron Variant

VCF File #5

Status: ✓

Validation status: ✓

Original filename: **Patient3852_IMGZ.vcf**

Received at: **October 12, 2021**

Updated at: **October 12, 2021**

Associated patient: **IMGZ_PATIENT_1** >

Collection method

UPDATE

Validation messages

No data

Table 1. Standardized core dataset. **(A)** Established data catalogues and data sources used in *SwissGenVar*.

Information	Data source	Obtained by	Full name	Description
Clinical indication	HPO [36]	Manual entry	Human Phenotype Ontology	key phenotype leading to genetic evaluation selected from standardized vocabulary of phenotypic abnormalities encountered in human disease
ClinVar clinical significance	ClinVar [28]	Variant Effect Predictor (VEP)	ClinVar	public archive of reports of the relationships among human variations and phenotypes, with supporting evidence
Clinical significance	ACMG [37]	Manual entry	American College of Medical Genetics	ACMG five-tiered classification system for variants: pathogenic, likely pathogenic, uncertain significance, likely benign, benign
Diagnosis	OMIM [38]	Manual entry	Online Mendelian Inheritance in Man	monogenic etiologic diagnosis
Ethnicity (self-reported)	gnomAD [39] categories	Manual entry	Genome Aggregation Database	gnomAD populations: African/African American, Amish, Latino/Admixed American, Ashkenazi Jewish, East Asian, Finnish, Non-Finnish European, Middle Eastern, South Asian, other
Frequency	gnomAD	VEP	Genome Aggregation Database	gnomAD global minor allele frequency (MAF)
Gene name	HGNC [40]	VEP	Human Genome Organisation Gene Nomenclature Committee	unique gene name according to the HUGO gene nomenclature
Inheritance of the disease	OMIM categories	Manual entry	Online Mendelian Inheritance in Man	OMIM categories: AD - autosomal dominant, AR - autosomal recessive, PD - pseudoautosomal dominant, PR - pseudoautosomal recessive, DD - digenic dominant, DR - digenic recessive, IC - isolated cases, ICB - inherited chromosomal imbalance, Mi - mitochondrial, Mu - multifactorial, SMO - somatic mosaicism, SMu - somatic mutation, XL - X-linked, XLD - X-linked dominant, XLR - X-linked recessive, YL - Y-linked
Inheritance of the variant	following DECIPHER [31] categories	Manual entry	Database of genomic variation and Phenotype in Humans using Ensembl Resources	following DECIPHER categories: de novo constitutive; de novo mosaic; paternally inherited, constitutive in father; paternally inherited, mosaic in father; maternally inherited, constitutive in mother; maternally inherited, mosaic in mother; biparental; imbalance arising from a balanced parental rearrangement; inherited mosaic; unknown
Phenotype	HPO	Manual entry	Human Phenotype Ontology	Detailed clinical features selected from standardized vocabulary of phenotypic abnormalities encountered in human disease
Transcripts	RefSeq [41], Ensembl [42]	VEP	NCBI Reference Sequence Database; Ensembl	RefSeq: a comprehensive, integrated, non-redundant, well-annotated set of reference sequences including genomic, transcript, and protein. Ensembl: a genome browser for vertebrate genomes that supports research in comparative genomics, evolution, sequence variation and transcriptional regulation.
Variant description	HGVS [27]	VEP	Human Genome Variation Society	This nomenclature is used for the description of sequence variants (namely HGVSg, HGVSc, and HGVSs)

Table 1. Standardized core dataset. **(B)** Internal data catalogues defined for *SwissGenVar*.

Information	Possible values	Remark
Age at onset	-1 (prenatal), 0, 0.1, 0.2, ..., 100	range of numbers for the age of onset in years
Aneuploidies	yes; no	
Canton	list of Swiss cantons, plus "non-Swiss"	
Causality	causative; likely causative; probably not causative; not causative; VUS; variant in a GUS	causality following clinical judgement
Chromosomal sex	XX; XY; other	
Clinical gender	male, female, ambiguous, transgender	
Karyotypic sex	45X, 46XX, 46XY, 47XXY, 47XYY, 47XXX (intended as expandable list)	content is conditional to the value of "other" in "Chromosomal sex"
Clinical status	affected; partially affected; potentially affected; not affected	defined fields/filters: "clinical status change to"; "clinical status at last clinical assessment"
Co-occurrences	yes; no	co-occurrence of more than one causative variant
Collection method	case-control; clinical testing; reference population; research; other; unknown	
Cytogenetic location	the cytogenetic location of the variant displayed as CHROM_NUMBERq/pCYTOGENETIC_BAND	
Detection method	sequencing; fragment analysis; Southern Blot; conventional cytogenetics; FISH (IFISH or MFISH); Array (Oligo or SNP); qRT-PCR; MLPA; NGS-based CNV detection (Panel/WES/WGS); other; not performed	
Gene locus type	protein-coding gene; non-coding RNA gene; long non-coding RNA; microRNA; ribosomal RNA; transfer RNA; small nuclear RNA; small nucleolar RNA; other; locus subjected to imprinting	partly coming from HUGO Gene Nomenclature Committee (HGNC) [40]
Index patient	yes; no	
Location	genomic position	GRCh37 as genome reference built [43]
Locus subjected to imprinting	yes; no; unknown	
Patient identifier (ID)	the patient ID refers to an internal <i>SwissGenVar</i> specific unique identifier that is generated when the patient is created in the system	patient/sample ID of the submitting institution is recorded as well
Submitting institution	one acronym per partner institution	

Table 1 (B) continued

Information	Possible values	Remark
Variant effect	missense variant; nonsense variant; splice region variant; splice acceptor variant; splice donor variant; regulatory region variant; promoter region variant; inframe insertion; inframe deletion; intron variant; synonymous variant; stop lost variant; start lost variant; frameshift variant; upstream gene variant; downstream gene variant; intergenic variant; non-coding transcript exon variant; TF binding site variant; 5' UTR variant; 3' UTR variant; exon deletion; exon duplication; contiguous gene deletion; contiguous gene duplication	adapted to Sequence Ontology (SO) [44] terms
Variant location	coding region; splicing region; 5' UTR; 3' UTR; upstream gene; downstream gene; promoter region; intronic region; regulatory region; intergenic region	
Variant type	CNV – amplification; CNV – deletion; CNV - insertion/duplication; complex rearrangement; conversion; deletion; deletion-insertion; duplication; insertion; methylation/epigenetic change; repeat variation; structural variant; substitution	
Variant zygosity	heterozygous; homozygous; hemizygous; mitochondrial heteroplasmy; mitochondrial homoplasmy; unknown; mosaic; chimeric; ambiguous	

CNV, copy number variation; FISH, fluorescence in situ hybridisation (IFISH, interphase-FISH; MFISH, metaphase-FISH); GUS, gene of uncertain significance; MLPA, multiplex ligation-dependent probe amplification; qRT-PCR, quantitative reverse transcription PCR (polymerase chain reaction); SNP, single nucleotide polymorphism; TF, transcription factor; WES, whole-exome sequencing; WGS, whole-genome sequencing; VUS, variant of unclear significance; UTR, untranslated region

References

1. Andreu-Perez, J., Poon, C. C., Merrifield, R. D., Wong, S. T., Yang, G. Z. Big data for health. *IEEE J. Biomed. Health Inform.* **2015**, *19*, 1193-1208; DOI: 10.1109/jbhi.2015.2450362.
2. Bíró, K., Dombrádi, V., Jani, A., Boruzs, K., Gray, M. Creating a common language: defining individualized, personalized and precision prevention in public health. *J. Public Health (Oxf.)*. **2018**, *40*, e552-e559; DOI: 10.1093/pubmed/fdy066.
3. Hasanzad, M., Sarhangi, N., Naghavi, A., Ghavimehr, E., Khatami, F., Ehsani Chimeh, S., Larijani, B., Aghaei Meybodi, H. R. Genomic medicine on the frontier of precision medicine. *J. Diabetes Metab. Disord.* **2022**, *21*, 853-861; DOI: 10.1007/s40200-021-00880-6.
4. Snyderman, R. Personalized health care: from theory to practice. *Biotechnol. J.* **2012**, *7*, 973-979; DOI: 10.1002/biot.201100297.
5. Lek, M., Hmeljak, J., Hooper, K. M. Genetic variance in human disease - modelling the future of genomic medicine. *Dis. Model Mech.* **2022**, *15*; DOI: 10.1242/dmm.049700.
6. Zuk, O., Hechter, E., Sunyaev, S. R., Lander, E. S. The mystery of missing heritability: Genetic interactions create phantom heritability. *Proc. Natl. Acad. Sci. USA.* **2012**, *109*, 1193-1198; DOI: 10.1073/pnas.1119675109.
7. Bomba, L., Walter, K., Soranzo, N. The impact of rare and low-frequency genetic variants in common disease. *Genome Biol.* **2017**, *18*, 77; DOI: 10.1186/s13059-017-1212-4.
8. Starita, L. M., Ahituv, N., Dunham, M. J., Kitzman, J. O., Roth, F. P., Seelig, G., Shendure, J., Fowler, D. M. Variant Interpretation: Functional Assays to the Rescue. *Am. J. Hum. Genet.* **2017**, *101*, 315-325; DOI: 10.1016/j.ajhg.2017.07.014.
9. Hoskinson, D. C., Dubuc, A. M., Mason-Suares, H. The current state of clinical interpretation of sequence variants. *Curr. Opin. Genet. Dev.* **2017**, *42*, 33-39; DOI: 10.1016/j.gde.2017.01.001.
10. Thouvenot, P., Ben Yamin, B., Fourrière, L., Lescure, A., Boudier, T., Del Nery, E., Chauchereau, A., Goldgar, D. E., Houdayer, C., Stoppa-Lyonnet, D., et al. Functional Assessment of Genetic Variants with Outcomes Adapted to Clinical Decision-Making. *PLoS Genet.* **2016**, *12*, e1006096; DOI: 10.1371/journal.pgen.1006096.
11. Sohail, M., Maier, R. M., Ganna, A., Bloemendal, A., Martin, A. R., Turchin, M. C., Chiang, C. W., Hirschhorn, J., Daly, M. J., Patterson, N., et al. Polygenic adaptation on height is overestimated due to uncorrected stratification in genome-wide association studies. *Elife.* **2019**, *8*; DOI: 10.7554/eLife.39702.
12. Shah, N., Hou, Y. C., Yu, H. C., Sainger, R., Caskey, C. T., Venter, J. C., Telenti, A. Identification of Misclassified ClinVar Variants via Disease Population Prevalence. *Am. J. Hum. Genet.* **2018**, *102*, 609-619; DOI: 10.1016/j.ajhg.2018.02.019.
13. Park, K. J., Lee, W., Chun, S., Min, W. K. The Frequency of Discordant Variant Classification in the Human Gene Mutation Database: A Comparison of the American College of Medical Genetics and Genomics Guidelines and ClinVar. *Lab. Med.* **2021**, *52*, 250-259; DOI: 10.1093/labmed/lmaa072.
14. Johnston, J. J., Biesecker, L. G. Databases of genomic variation and phenotypes: existing resources and future needs. *Hum. Mol. Genet.* **2013**, *22*, R27-31; DOI: 10.1093/hmg/ddt384.
15. Brookes, A. J., Robinson, P. N. Human genotype-phenotype databases: aims, challenges and opportunities. *Nat. Rev. Genet.* **2015**, *16*, 702-715; DOI: 10.1038/nrg3932.

16. Whole-genome sequence variation, population structure and demographic history of the Dutch population. *Nat. Genet.* **2014**, *46*, 818-825; DOI: 10.1038/ng.3021.
17. Bauer, P., Karges, E., Oprea, G., Rolfs, A. Unmet needs in human genomic variant interpretation. *Genet. Med.* **2018**, *20*, 376-377; DOI: 10.1038/gim.2017.187.
18. Thorogood, A., Cook-Deegan, R., Knoppers, B. M. Public variant databases: liability? *Genet. Med.* **2017**, *19*, 838-841; DOI: 10.1038/gim.2016.189.
19. Swiss Personalized Health Network (SPHN). Available online: <https://sphn.ch/> (accessed on 09 December 2022).
20. SwissGenVar project page. Available online: <https://sphn.ch/network/projects-old/infrastructure-development-projects/project-swissgenvar/> (accessed on 01 December 2022).
21. SPHN BioMedIT. Available online: <https://www.biomedit.ch/> (accessed on 09 December 2022).
22. SPHN Information Security Policy Available online: <https://sphn.ch/document/information-security-policy/> (accessed on 09 December 2022).
23. SPHN SETT. Available online: <https://gitlab.com/biomedit/sett> (accessed on 09 December 2022).
24. Keycloak Server Administration. Available online: https://www.keycloak.org/docs/latest/server_admin/ (accessed on 06 December 2022).
25. SWITCH eduID. Available online: <https://www.switch.ch/edu-id/> (accessed on 06 December 2022).
26. McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R., Thormann, A., Flicek, P., Cunningham, F. The Ensembl Variant Effect Predictor. *Genome Biol.* **2016**, *17*, 122; DOI: 10.1186/s13059-016-0974-4.
27. den Dunnen, J. T., Dalgleish, R., Maglott, D. R., Hart, R. K., Greenblatt, M. S., McGowan-Jordan, J., Roux, A. F., Smith, T., Antonarakis, S. E., Taschner, P. E. HGVS Recommendations for the Description of Sequence Variants: 2016 Update. *Hum. Mutat.* **2016**, *37*, 564-569; DOI: 10.1002/humu.22981.
28. Landrum, M. J., Lee, J. M., Benson, M., Brown, G. R., Chao, C., Chitipiralla, S., Gu, B., Hart, J., Hoffman, D., Jang, W., et al. ClinVar: improving access to variant interpretations and supporting evidence. *Nucleic Acids Res.* **2018**, *46*, D1062-d1067; DOI: 10.1093/nar/gkx1153.
29. Sherry, S. T., Ward, M., Sirotkin, K. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. *Genome Res.* **1999**, *9*, 677-679; DOI.
30. Stenson, P. D., Ball, E. V., Mort, M., Phillips, A. D., Shiel, J. A., Thomas, N. S., Abeyasinghe, S., Krawczak, M., Cooper, D. N. Human Gene Mutation Database (HGMD): 2003 update. *Hum. Mutat.* **2003**, *21*, 577-581; DOI: 10.1002/humu.10212.
31. Firth, H. V., Richards, S. M., Bevan, A. P., Clayton, S., Corpas, M., Rajan, D., Van Vooren, S., Moreau, Y., Pettett, R. M., Carter, N. P. DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. *Am. J. Hum. Genet.* **2009**, *84*, 524-533; DOI: 10.1016/j.ajhg.2009.03.010.
32. Fokkema, I. F., Taschner, P. E., Schaafsma, G. C., Celli, J., Laros, J. F., den Dunnen, J. T. LOVD v.2.0: the next generation in gene variant databases. *Hum. Mutat.* **2011**, *32*, 557-563; DOI: 10.1002/humu.21438.
33. Caucheteur, D., Gobeill, J., Mottaz, A., Pasche, E., Michel, P. A., Mottin, L., Stekhoven, D. J., Barbié, V., Ruch, P. Text-Mining Services of the Swiss Variant Interpretation Platform for Oncology. *Stud. Health Technol. Inform.* **2020**, *270*, 884-888; DOI: 10.3233/shti200288.

34. Ng, P. C., Henikoff, S. SIFT: Predicting amino acid changes that affect protein function. *Nucleic Acids Res.* **2003**, *31*, 3812-3814; DOI: 10.1093/nar/gkg509.
35. Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., Sunyaev, S. R. A method and server for predicting damaging missense mutations. *Nat. Methods.* **2010**, *7*, 248-249; DOI: 10.1038/nmeth0410-248.
36. Köhler, S., Gargano, M., Matentzoglou, N., Carmody, L. C., Lewis-Smith, D., Vasilevsky, N. A., Danis, D., Balagura, G., Baynam, G., Brower, A. M., et al. The Human Phenotype Ontology in 2021. *Nucleic Acids Res.* **2021**, *49*, D1207-d1217; DOI: 10.1093/nar/gkaa1043.
37. Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.* **2015**, *17*, 405-424; DOI: 10.1038/gim.2015.30.
38. Online Mendelian Inheritance in Man, OMIM. Available online: <https://omim.org/> (accessed on 05 December 2022).
39. Genome Aggregation Database (gnomAD). Available online: <https://gnomad.broadinstitute.org/> (accessed on 06 December 2022).
40. Human Genome Organisation (HUGO) Gene Nomenclature Committee at the European Bioinformatics Institute. Available online: <https://www.genenames.org/> (accessed on 05 December 2022).
41. O'Leary, N. A., Wright, M. W., Brister, J. R., Ciufu, S., Haddad, D., McVeigh, R., Rajput, B., Robbertse, B., Smith-White, B., Ako-Adjei, D., et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. *Nucleic Acids Res.* **2016**, *44*, D733-745; DOI: 10.1093/nar/gkv1189.
42. Cunningham, F., Allen, J. E., Allen, J., Alvarez-Jarreta, J., Amode, M. R., Armean, I. M., Austine-Orimoloye, O., Azov, A. G., Barnes, I., Bennett, R., et al. Ensembl 2022. *Nucleic Acids Res.* **2022**, *50*, D988-d995; DOI: 10.1093/nar/gkab1049.
43. Church, D. M., Schneider, V. A., Graves, T., Auger, K., Cunningham, F., Bouk, N., Chen, H. C., Agarwala, R., McLaren, W. M., Ritchie, G. R., et al. Modernizing reference genome assemblies. *PLoS Biol.* **2011**, *9*, e1001091; DOI: 10.1371/journal.pbio.1001091.
44. Eilbeck, K., Lewis, S. E., Mungall, C. J., Yandell, M., Stein, L., Durbin, R., Ashburner, M. The Sequence Ontology: a tool for the unification of genome annotations. *Genome Biol.* **2005**, *6*, R44; DOI: 10.1186/gb-2005-6-5-r44.
45. Field, M. A. Bioinformatic Challenges Detecting Genetic Variation in Precision Medicine Programs. *Front. Med. (Lausanne)*. **2022**, *9*, 806696; DOI: 10.3389/fmed.2022.806696.
46. Maffucci, P., Bigio, B., Rapaport, F., Cobat, A., Borghesi, A., Lopez, M., Patin, E., Bolze, A., Shang, L., Bendavid, M., et al. Blacklisting variants common in private cohorts but not in public databases optimizes human exome analysis. *Proc. Natl. Acad. Sci. USA*. **2019**, *116*, 950-959; DOI: 10.1073/pnas.1808403116.
47. SPHN Data Coordination Center (DCC). Available online: <https://sphn.ch/de/projects/data-coordination-center/> (accessed on 10 December 2022).